{"news_desk": "Business", "print_page": "3", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Amarin Pharma brings novel free-speech suit against Food and Drug Administration, saying agency has no constitutional grounds to bar pharmaceutical companies from discussing off-label medication usage with doctors; argues FDA has no right to bar transmission of accurate information, but critics say promotion of off-label use dangerously sidesteps agency's authority.", "type_of_material": "News", "word_count": "944", "lead_paragraph": "Amarin Pharma says it has a constitutional right to share information on unapproved uses of its products, a practice the government frowns on.", "pub_date": "2015-05-08T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Drugmaker Sues F.D.A. Over Right to Discuss Off-Label Uses", "print_headline": "Drugmaker Sues F.D.A. to Discuss Off-Label Uses"}, "snippet": "Amarin Pharma says it has a constitutional right to share information on unapproved uses of its products, a practice the government frowns on.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/05/08/business/drugmaker-sues-fda-over-right-to-discuss-off-label-uses.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Amarin Corp PLC", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "4", "is_major": "Y", "value": "Freedom of Speech and Expression", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Labeling and Labels (Product)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Suits and Litigation (Civil)", "name": "subject"}], "blog": [], "_id": "554bd09a38f0d87a4d2b58be", "source": "The New York Times"}